Redeye comments on Spago Nanomedical’s Q2 2023 report. We note that a complete analysis of the study results of SPAGOPIX-02 still awaits. In the short- to medium-term, positive efficacy read-out from SPAGOPIX-02 would provide a moderate upward swing in the share as the cash position is slowly running short, which should fuel some worries about the continued financing of the company and its projects.
